RaQualia Pharma Inc.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
RaQualia Pharma Inc. owes ¥0.29 for every ¥1 it owns. RaQualia Pharma Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in Japan · latest annual results Dec 2025.
P/E ratio
71.3Investors pay ¥71.3 for every ¥1 of RaQualia Pharma Inc.'s yearly profit, higher than 94% of Healthcare companies in Japan.
P/B ratio
2.07The share price is 2.07 times RaQualia Pharma Inc.'s book value per share, higher than 66% of Healthcare companies in Japan.
Market cap
¥16.2 BThe total market value of all of RaQualia Pharma Inc.'s shares at today's price (share price × number of shares), smaller than 51% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥7.8 BWhat RaQualia Pharma Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥300.83Net worth divided by the number of shares. The share price of ¥624.00 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
2.3%RaQualia Pharma Inc. earned 2.3% on its shareholders' money over the last year, lower than 68% of Healthcare companies in Japan.
Owes vs Owns
0.29×RaQualia Pharma Inc. owes ¥0.29 for every ¥1 it owns (low), lower than 62% of Healthcare companies in Japan.
Dividend yield
NoneRaQualia Pharma Inc. does not currently pay a dividend.
Revenue growth
+28%Revenue rose 28% in the year to Dec 2025, and grew 11% a year on average over 3 years.
Profit growth
Back to profitRaQualia Pharma Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
6.9%RaQualia Pharma Inc. keeps ¥7 of every ¥100 of revenue as net profit.
Cash quality
-1.3×Cash from RaQualia Pharma Inc.'s business was -1.3× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Interest cover
8.2×RaQualia Pharma Inc.'s operating profit covered its interest costs 8.2 times in the year to Dec 2025.
Cash vs debt
Net cashRaQualia Pharma Inc. held ¥342 M more cash than debt (net cash) at Dec 2025.
Questions
What is RaQualia Pharma Inc.'s P/E ratio?
Investors pay ¥71.3 for every ¥1 of RaQualia Pharma Inc.'s yearly profit, higher than 94% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For RaQualia Pharma Inc.: ¥16.2 B ÷ ¥7.8 B (30 Jun 2026) = 2.1.
What is RaQualia Pharma Inc.'s return on equity?
RaQualia Pharma Inc. earned 2.3% on its shareholders' money over the last year, lower than 68% of Healthcare companies in Japan.
How much does RaQualia Pharma Inc. owe compared with what it owns?
RaQualia Pharma Inc. owes ¥0.29 for every ¥1 it owns (low), lower than 62% of Healthcare companies in Japan.
Does RaQualia Pharma Inc. pay a dividend?
No. RaQualia Pharma Inc. does not currently pay a dividend.
Is RaQualia Pharma Inc.'s revenue growing?
Revenue rose 28% in the year to Dec 2025, and grew 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.